Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer
Introduction
Accurate staging of lung cancer is essential for patient management and in determining the optimal therapeutic strategy [1]. Clinical staging at the time of presentation is typically performed using a series of targeted diagnostic imaging studies including computed tomography (CT) of the thorax through the liver and adrenal glands, CT and/or magnetic resonance (MR) imaging of the head, and radionuclide bone scintigraphy (bone scan). More recently, whole-body 2-deoxy-2-[]fluoro-d-glucose (FDG) with positron-emission tomography (PET) has been suggested as an alternative study, which could provide a more accurate and efficient diagnostic approach than the combination of conventional imaging studies [2]. PET scanning has become an accepted tool for evaluation of regional lymph nodes, and some studies have shown it to be beneficial for extra-thoracic staging in the overall search of metastatic disease [3], [4], [5], [6]. More specifically, given the ability of PET to detect osseous metastasis, several small series have suggested that the high accuracy of PET may obviate the need for a bone scan [6], [7], [8], [9]. The purpose of this study was to compare the agreement and accuracy of PET scan to bone scans for the detection of distant bone metastases in patients with newly diagnosed lung cancer to determine if these were complementary or redundant studies.
Section snippets
Patient selection
The tumor registry and PET database at our institution were retrospectively reviewed to identify all patients with a pathologically proved new diagnosis of lung cancer and staging with both whole-body PET and bone scan prior to the initiation of therapy. Lung cancer patients at our institution routinely receive staging PET scans in the thoracic surgery clinic and staging bone scan in the thoracic oncology clinic. The review included 1100 patients with lung cancer diagnosed between July 1998 and
Patients
Lung cancer histology and stage distribution is listed in Table 1. One hundred and four (40%) of the 257 patients presented with stage IV disease, and 57 (22%) patients had osseous metastases by clinical–pathologic correlation.
PET scan
PET scan was considered positive for bone metastasis in 61 (24%) and negative in 196 (76%) patients. The sensitivity, specificity, and positive and negative predictive values of PET were 91% (95% CI, 81–97%), 96% (95% CI, 92–98%), 85% (95% CI, 74–93%), and 97% (95% CI,
Discussion
Once a new diagnosis of lung cancer has been established, an accurate assessment of the stage becomes crucial for deciding on treatment options and providing prognostic information. Conventional imaging studies are clearly less than optimal, as evidenced by the approximately 60% 5-year survival rates of patients initially diagnosed with early stage lung cancer [13]. These patients typically undergo curative resection, because there is no evidence for metastases, but almost 40% later recur with
References (16)
- et al.
Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial
Lancet
(2002) - et al.
Comparison of bone and 2-deoxy-2-18F-fluoro-d-glucose positron emission tomography in the evaluation of bony metastases in lung cancer
Mol. Imag. Biol.
(2003) - et al.
Noninvasive staging of non-small cell lung cancer: a review of the current evidence
Chest
(2003) - et al.
Classification, staging, and prognosis of lung cancer
Eur. J. Radiol.
(2003) - et al.
Extra-thoracic staging of lung cancer
Eur. J. Radiol.
(2002) - et al.
Preoperative staging of non-small cell lung cancer with positron-emission tomography
N. Engl. J. Med.
(2000) - et al.
Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis
JAMA
(2001) - et al.
Staging non-small cell lung cancer with whole-body PET
Radiology
(1999)
Cited by (135)
PET imaging of lung and pleural cancer
2022, Nuclear Medicine and Molecular Imaging: Volume 1-4Management guidelines for stage III non-small cell lung cancer
2021, Critical Reviews in Oncology/HematologyACR Appropriateness Criteria <sup>®</sup> Noninvasive Clinical Staging of Primary Lung Cancer
2019, Journal of the American College of RadiologyNew insights into designing hybrid nanoparticles for lung cancer: Diagnosis and treatment
2019, Journal of Controlled ReleaseClinical Presentation and Prognostic Factors in Lung Cancer
2018, IASLC Thoracic Oncology